C92.A2
Acute myeloid leukemia with multilineage dysplasia, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Acute myeloid leukemia (AML) with multilineage dysplasia is a type of blood cancer characterized by the abnormal growth of myeloid cells in the bone marrow, leading to poor blood cell production. When this condition occurs again after treatment, it is called a relapse. This specific diagnosis, coded as C92.A2 in the ICD-10 system, indicates that the leukemia has recurred, and there are abnormal developments across multiple blood cell lineages. Understanding this form of AML can help patients and caregivers be more familiar with its nature, symptoms, and treatment options.
Causes & Symptoms
Clinical Causes: Previous exposure to chemotherapy or radiation therapy Genetic mutations that predispose to leukemia Environmental factors such as exposure to benzene or other toxins Inherited genetic disorders Progression of other myelodysplastic syndromes
Key Symptoms: Persistent fatigue and weakness Unusual bleeding or bruising Frequent infections due to low white blood cell counts Pale skin Shortness of breath Fever or chills Bone or joint pain Easy bruising or bleeding gums Night sweats and unexplained weight loss General malaise
Diagnostic & Treatment
Diagnosis Path: Diagnosing AML with multilineage dysplasia involves multiple steps including blood tests such as a complete blood count (CBC), which often shows abnormal levels of different types of blood cells. A bone marrow biopsy is essential to examine the marrow for abnormal proliferation of myeloid cells and to identify dysplastic features across different lineages. Additional tests like cytogenetic analysis and molecular studies are used to identify specific genetic mutations that can influence prognosis and treatment decisions. Because the disease has relapsed, doctors also perform assessments to determine the extent of the recurrence and whether the disease has spread or transformed.
Treatment Protocols: Salvage chemotherapy to reduce cancer cell burden Targeted therapy, if specific mutations are identified Bone marrow or stem cell transplantation, especially in eligible patients Supportive care such as blood transfusions and antibiotics to manage symptoms Clinical trials exploring new treatments and drugs
Clinical Advice & FAQs
Billing Guidance
Is C92.A2 a billable ICD-10 code?
Yes, C92.A2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.A2?
Clinical documentation must specify the nature of Acute myeloid leukemia with multilineage dysplasia, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference